Opendata, web and dolomites

BlueDot SIGNED

A long-acting, constant release ocular implant for the sustained delivery of biologics and small molecules for the treatment of retinal diseases.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "BlueDot" data sheet

The following table provides information about the project.

Coordinator
MICROSERT LTD 

Organization address
address: 24 HASHOSHANIM STREET
city: NESHER
postcode: 3684224
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MICROSERT LTD IL (NESHER) coordinator 50˙000.00

Map

 Project objective

Seventy-six million people will suffer from blindness by 2020. Age-related retinal disorders - macular degeneration (AMD) and diabetic macular edema (DME) are two of the leading causes of blindness in the world. About 200,000 new cases of advanced, age-related AMD identified each year in the United States and between 14.9 and 21.5 million cases of early AMD, and between 3.9 and 4.8 million cases of late AMD is expected in Europe by 2040. The complexity of eye anatomy presents challenges for treatment. Current treatment, intravitreal injections (IVI) are the highest growth medical procedure in the globe, with an estimated 20 million intravitreal injections globally in 2016. Ranibizumab, treatment blocking vascular endothelial growth factor (VEGF), which promotes blood vessel growth, costs approximately $2,000 in USA and €1000 per injection. Patients may need up to 12 injection per year. Additionally, this treatment significantly affects patient comfort. MicroSert has developed BlueDot – a novel, long-acting release (LAR) ocular implant for the sustained delivery of biologics and small molecules for the treatment of retinal diseases. BlueDot is implantable to the tear duct and releases therapeutic inside the eye. Implantation requires one-step office-based procedure using proprietary implantation device with safety monitoring system and with no incision needed. BlueDot is refillable and lasts up to two years. The SME-I Phase 1 project perfectly suits the innovation’s current stage of development and overall business strategy allowing MicroSert to check final specifications of BlueDot, establish a sound business development and gain partners necessary for the Phase II study.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BLUEDOT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BLUEDOT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

BEMYEYES (2019)

Specialized Help from Be My Eyes – harnessing technology to connect companies directly with their blind and visually impaired users

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

CyreenApplication (2019)

Connecting Ad-Impressions with Purchase. The new advanced Advertisement at the point of sales.

Read More